Madrigal Pharmaceuticals (Nasdaq:MDGL) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MDGL 주식 개요

임상 단계의 바이오 제약 회사인 마드리갈 파마슈티컬스는 미국에서 비알코올성 지방간염(NASH) 치료를 위한 치료제 개발에 주력하고 있습니다.

MDGL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	5/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 87.9% 에서 거래

수익은 매년 64.33% 증가할 것으로 예상됩니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 1년 동안 주주가 희석되었습니다.

Madrigal Pharmaceuticals, Inc. 경쟁사

Summit Therapeutics

NasdaqGM:SMMT

US$7.6b

Krystal Biotech

NasdaqGS:KRYS

US$6.0b

Exelixis

NasdaqGS:EXEL

US$6.8b

Viking Therapeutics

NasdaqCM:VKTX

US$6.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Madrigal Pharmaceuticals
과거 주가
현재 주가	US$278.48
52주 최고치	US$299.98
52주 최저치	US$119.76
베타	-0.43
11개월 변경	2.51%
3개월 변경 사항	21.16%
1년 변경 사항	44.09%
33년 변화	213.53%
5년 변화	207.85%
IPO 이후 변화	2,643.62%

최근 뉴스 및 업데이트

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Jun 09

Recent updates

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Jun 09

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Apr 24

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Mar 15

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Feb 07

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

May 11

Madrigal: NASH Data In Q4 Is The Key

Apr 19

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Feb 24

Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come

Jan 31

Madrigal: Powerful Catalyst Approaching

Jan 09

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Nov 08

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Jul 26

Madrigal Pharmaceuticals: Leading The NASH Innovation

May 05

Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation

Apr 12

We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth

Dec 28

Madrigal Pharma: A Look At The Early MAESTRO Trial Data

Nov 27

Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow

Nov 17

Madrigal Pharmaceuticals EPS misses by $0.40

Nov 05

주주 수익률

	MDGL	US Biotechs	US 마켓
7D	-1.8%	-0.3%	2.1%
1Y	44.1%	17.2%	20.5%

수익률 대 산업: MDGL 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: MDGL 지난 1년 동안 23.6 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is MDGL's price volatile compared to industry and market?
MDGL volatility
MDGL Average Weekly Movement	7.4%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.6%
10% least volatile stocks in US Market	3.0%

안정적인 주가: MDGL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MDGL 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
n/a	376	Bill Sibold	www.madrigalpharma.com

임상 단계의 바이오 제약 회사인 마드리갈 파마슈티컬스는 미국에서 비알코올성 지방간염(NASH) 치료를 위한 치료제 개발에 주력하고 있습니다. 주요 제품 후보로는 간 지향성 갑상선 호르몬 수용체 베타 작용제인 레스메티롬이 있으며, NASH 치료를 위한 임상 3상 시험을 진행 중입니다. 본사는 펜실베이니아주 웨스트 콘쇼호켄에 있습니다.

Madrigal Pharmaceuticals, Inc. 기본 사항 요약

Madrigal Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MDGL 기본 통계
시가총액	US$6.07b
수익(TTM)	-US$444.27m
수익(TTM)	n/a

0.0x

P/S 비율

-13.4x

P/E 비율

MDGL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MDGL 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$444.28m
수익	-US$444.27m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

Aug 07, 2024

주당 순이익(EPS)	-20.85
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	13.7%

MDGL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MDGL 주식 개요

보상

위험 분석

Madrigal Pharmaceuticals, Inc. 경쟁사

NasdaqGM:SMMT

US$7.6b

NasdaqGS:KRYS

US$6.0b

NasdaqGS:EXEL

US$6.8b

NasdaqCM:VKTX

US$6.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Recent updates

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

Independent Lead Director notifies of intention to sell stock

Forecast to breakeven in 2026

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Independent Director notifies of intention to sell stock

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Consensus EPS estimates fall by 11%

Price target increased by 18% to US$383

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Consensus revenue estimates fall by 14%

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Insider exercised options and sold US$513k worth of stock

Senior VP & General Counsel exercised options and sold US$894k worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Price target increased by 7.4% to US$341

Insider exercised options and sold US$1.9m worth of stock

Consensus revenue estimates fall by 92%

Independent Director exercised options and sold US$4.3m worth of stock

Senior VP & General Counsel exercised options and sold US$2.5m worth of stock

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Price target increased to US$164

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

Madrigal: Buy And Hoard Before Q4 Data Readout

Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate